| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/5/2026 | $55.00 | Buy | Tigress Financial |
| 1/21/2026 | $50.00 → $55.00 | Buy | BTIG Research |
| 1/12/2026 | $48.00 | Buy | Citigroup |
| 1/12/2026 | $38.00 | Neutral | BNP Paribas Exane |
| 1/12/2026 | $50.00 | Overweight | Analyst |
| 1/12/2026 | $50.00 | Overweight | Piper Sandler |
| 1/12/2026 | $48.00 | Overweight | Morgan Stanley |
| 1/12/2026 | $47.00 | Outperform | RBC Capital Mkts |
| 1/12/2026 | $48.00 | Outperform | Mizuho |
| 1/12/2026 | $46.00 | Buy | TD Cowen |
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
4 - Medline Inc. (0002046386) (Issuer)
4 - Medline Inc. (0002046386) (Issuer)
4 - Medline Inc. (0002046386) (Issuer)
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
3 - Medline Inc. (0002046386) (Issuer)
3 - Medline Inc. (0002046386) (Issuer)
4 - Medline Inc. (0002046386) (Issuer)
4 - Medline Inc. (0002046386) (Issuer)
3 - Medline Inc. (0002046386) (Issuer)
4 - Medline Inc. (0002046386) (Issuer)
3 - Medline Inc. (0002046386) (Issuer)
3 - Medline Inc. (0002046386) (Issuer)
4 - Medline Inc. (0002046386) (Issuer)
3 - Medline Inc. (0002046386) (Issuer)
S-1 - Medline Inc. (0002046386) (Filer)
S-8 - Medline Inc. (0002046386) (Filer)
10-K - Medline Inc. (0002046386) (Filer)
8-K - Medline Inc. (0002046386) (Filer)
SCHEDULE 13G - Medline Inc. (0002046386) (Subject)
SCHEDULE 13G - Medline Inc. (0002046386) (Subject)
SCHEDULE 13G - Medline Inc. (0002046386) (Subject)
SCHEDULE 13G - Medline Inc. (0002046386) (Subject)
SCHEDULE 13G - Medline Inc. (0002046386) (Subject)
8-K - Medline Inc. (0002046386) (Filer)
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Tigress Financial initiated coverage of Medline with a rating of Buy and set a new price target of $55.00
BTIG Research reiterated coverage of Medline with a rating of Buy and set a new price target of $55.00 from $50.00 previously
Citigroup initiated coverage of Medline with a rating of Buy and set a new price target of $48.00
BNP Paribas Exane initiated coverage of Medline with a rating of Neutral and set a new price target of $38.00
Piper Sandler initiated coverage of Medline with a rating of Overweight and set a new price target of $50.00
Morgan Stanley initiated coverage of Medline with a rating of Overweight and set a new price target of $48.00
Analyst initiated coverage of Medline with a rating of Overweight and set a new price target of $50.00
RBC Capital Mkts initiated coverage of Medline with a rating of Outperform and set a new price target of $47.00
Mizuho initiated coverage of Medline with a rating of Outperform and set a new price target of $48.00
TD Cowen initiated coverage of Medline with a rating of Buy and set a new price target of $46.00
Fastest customizable press release news feed in the world
NORTHFIELD, Ill., March 03, 2026 (GLOBE NEWSWIRE) -- Medline Inc. (NASDAQ:MDLN) ("Medline") announced today that certain selling stockholders affiliated with Blackstone Inc., The Carlyle Group Inc., Hellman & Friedman LLC and a wholly owned subsidiary of the Abu Dhabi Investment Authority (the "Selling Stockholders") have commenced an underwritten public offering of 75,000,000 shares of Medline's Class A common stock pursuant to a registration statement filed with the Securities and Exchange Commission (the "SEC"). Additionally, the Selling Stockholders intend to grant the underwriters a 30-day option to purchase up to an additional 11,250,000 shares of Medline's Class A common stock. Med
Delivered strong full year 2025 resultsCompleted Initial Public OfferingIntroduced full year 2026 guidanceFourth quarter net sales of $7.8 billion, an increase of 14.8%Fourth quarter net income of $180 million, a decrease of 37.7%Fourth quarter Adjusted EBITDA1 of $805 million, approximately flatFull year net sales of $28.4 billion, an increase of 11.5%Full year net income of $1.2 billion, a decrease of 3.6%Full year Adjusted EBITDA1 of $3.5 billion, an increase of 3.2% NORTHFIELD, Ill., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Medline Inc. ("Medline" or the "Company") (NASDAQ:MDLN), the largest provider of medical-surgical ("med-surg") products and supply chain solutions serving all points of c
NORTHFIELD, Ill., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Medline Inc. ("Medline") (NASDAQ:MDLN) today announced that Jim Boyle, Chief Executive Officer, and Mike Drazin, Chief Financial Officer, are scheduled to present at the Barclays 28th Annual Global Healthcare Conference in Miami Beach, FL, on Wednesday, March 11, 2026, at 9:30am ET. A webcast of the presentation will be available on the Events page of Medline's Investor Relations website at ir.medline.com. A replay of the webcast will be available on Medline's Investor Relations website for six months following the event. About MedlineMedline is the largest provider of medical-surgical products and supply chain solutions serving all poi
NORTHFIELD, Ill., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Medline Inc. ("Medline") (NASDAQ:MDLN) today announced that it plans to report fourth quarter and full year 2025 financial results on Wednesday, February 25, 2026. A press release and supplemental materials will be issued before the market opens. The company will host a webcast and conference call at 9:30am ET/ 8:30am CT to discuss the financial results. Information about Medline's financial results, including a link to the live webcast, will be available on the Events page of Medline's Investor Relations website at ir.medline.com. A replay of the webcast will be available following the event through the same website. About MedlineMedli
NORTHFIELD, Ill., Dec. 30, 2025 (GLOBE NEWSWIRE) -- Medline Inc. ("Medline") (NASDAQ:MDLN) today announced that Jim Boyle, Chief Executive Officer, and Mike Drazin, Chief Financial Officer, are scheduled to present at the J.P. Morgan Healthcare Conference in San Francisco, Calif., on Tuesday, January 13, 2026, at 3:00 pm Pacific Time. The presentation will be available on the Events page of Medline's Investor Relations website at ir.medline.com. A replay of the webcast will be available on Medline's Investor Relations website for 30 days following the event. About MedlineMedline is the largest provider of medical-surgical ("med-surg") products and supply chain solutions serving all point
NORTHFIELD, Ill., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Medline Inc. (NASDAQ:MDLN) ("Medline") announced today that it has closed its upsized initial public offering of 248,439,654 shares of its Class A common stock at a public offering price of $29.00 per share, including the full exercise by the underwriters of their option to purchase up to an additional 32,405,172 shares of Class A common stock. Medline intends to use the proceeds (net of underwriting discounts) from the issuance of 179,000,000 shares to repay outstanding indebtedness under its senior secured term loan facilities and the remainder for general corporate purposes and to bear the expenses of the offering. Medline intends to
Live finance-specific insights
NORTHFIELD, Ill., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Medline Inc. ("Medline") (NASDAQ:MDLN) today announced that it plans to report fourth quarter and full year 2025 financial results on Wednesday, February 25, 2026. A press release and supplemental materials will be issued before the market opens. The company will host a webcast and conference call at 9:30am ET/ 8:30am CT to discuss the financial results. Information about Medline's financial results, including a link to the live webcast, will be available on the Events page of Medline's Investor Relations website at ir.medline.com. A replay of the webcast will be available following the event through the same website. About MedlineMedli